» Articles » PMID: 37386070

Mechanism of TNFα-induced Downregulation of Salt-inducible Kinase 2 in Adipocytes

Overview
Journal Sci Rep
Specialty Science
Date 2023 Jun 29
PMID 37386070
Authors
Affiliations
Soon will be listed here.
Abstract

Salt-inducible kinase 2 (SIK2) is highly expressed in white adipocytes, but downregulated in individuals with obesity and insulin resistance. These conditions are often associated with a low-grade inflammation in adipose tissue. We and others have previously shown that SIK2 is downregulated by tumor necrosis factor α (TNFα), however, involvement of other pro-inflammatory cytokines, or the mechanisms underlying TNFα-induced SIK2 downregulation, remain to be elucidated. In this study we have shown that TNFα downregulates SIK2 protein expression not only in 3T3L1- but also in human in vitro differentiated adipocytes. Furthermore, monocyte chemoattractant protein-1 and interleukin (IL)-1β, but not IL-6, might also contribute to SIK2 downregulation during inflammation. We observed that TNFα-induced SIK2 downregulation occurred also in the presence of pharmacological inhibitors against several kinases involved in inflammation, namely c-Jun N-terminal kinase, mitogen activated protein kinase kinase 1, p38 mitogen activated protein kinase or inhibitor of nuclear factor kappa-B kinase (IKK). However, IKK may be involved in SIK2 regulation as we detected an increase of SIK2 when inhibiting IKK in the absence of TNFα. Increased knowledge about inflammation-induced downregulation of SIK2 could ultimately be used to develop strategies for the reinstalment of SIK2 expression in insulin resistance.

Citing Articles

Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers.

Lin L, Wu Q, Lu F, Lei J, Zhou Y, Liu Y Front Oncol. 2023; 13:1184079.

PMID: 37810967 PMC: 10559910. DOI: 10.3389/fonc.2023.1184079.

References
1.
Waelchli R, Bollbuck B, Bruns C, Buhl T, Eder J, Feifel R . Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK. Bioorg Med Chem Lett. 2005; 16(1):108-12. DOI: 10.1016/j.bmcl.2005.09.035. View

2.
Sebolt-Leopold J, Herrera R . Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004; 4(12):937-47. DOI: 10.1038/nrc1503. View

3.
Pettersson A, Stenson B, Lorente-Cebrian S, Andersson D, Mejhert N, Kratzel J . LXR is a negative regulator of glucose uptake in human adipocytes. Diabetologia. 2013; 56(9):2044-54. DOI: 10.1007/s00125-013-2954-5. View

4.
Karin M . How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999; 18(49):6867-74. DOI: 10.1038/sj.onc.1203219. View

5.
Hermanson S, Carlson C, Riddle S, Zhao J, Vogel K, Nichols R . Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. PLoS One. 2012; 7(8):e43580. PMC: 3429506. DOI: 10.1371/journal.pone.0043580. View